• If you are wondering whether Corvus Pharmaceuticals stock still offers value after a big run, the next sections break down what the current price might imply about expectations.
• The stock recently closed at US$14.59, with a 1 year return of 335.5% and a year to date return of 99.3%, alongside a 4.0% decline over the last 7 days and a 1.7% gain over the past 30 days.
• Recent news coverage has focused on Corvus Pharmaceuticals within the context of its sector and ongoing product development pipeline. This helps frame how investors may be thinking about future prospects and risk. Commentary has also highlighted how smaller biotech stocks can see sharp price reactions when sentiment around clinical progress or funding conditions changes.
• Even with this attention, Corvus Pharmaceuticals currently has a valuation score of 2 out of 6. The next sections will compare different valuation approaches and then finish with a way to think about value that goes beyond any single model.

Corvus Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Corvus Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting a company’s future cash flows and discounting them back to today’s value using a required return.

For Corvus Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $32.97 million. Analyst and extrapolated projections show free cash flow staying negative in the near term, then turning positive, reaching $47.93 million in 2030. Beyond that, projections continue to rise, with discounted values provided out to 2035.

When all of these projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $42.20 per share. Compared with the recent share price of $14.59, this implies a discount of 65.4%, which indicates the stock is trading well below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Corvus Pharmaceuticals is undervalued by 65.4%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Corvus Pharmaceuticals Price vs Book

For companies where earnings can be volatile or negative, price to book, or P/B, is often a useful cross check because it compares the share price with the accounting value of net assets. It is still influenced by what investors expect for growth and risk, since higher expected returns on those assets can justify a higher multiple.

Growth expectations, balance sheet strength and perceived risk all feed into what investors view as a normal P/B range. Higher growth or lower risk can support a richer multiple, while more uncertainty can hold it down. Corvus Pharmaceuticals currently trades on a P/B of 20.05x. This sits well above the Biotechs industry average of 2.39x and above the peer group average of 12.81x, which signals that investors are paying a much higher price relative to book value than for many other stocks in the sector.

Simply Wall St’s Fair Ratio is a proprietary estimate of what P/B might be reasonable after considering factors such as earnings growth, profit margins, risk profile, industry and market cap. This can be more informative than a simple peer or industry comparison because it adjusts for company specific characteristics. In this case, the Fair Ratio is not available, so it is not possible to say whether the current 20.05x P/B looks high, low or about right against that tailored yardstick.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Corvus Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives let you attach a clear story about Corvus Pharmaceuticals to the numbers by linking your view of its pipeline, trial risks and funding needs to specific forecasts for revenue, earnings and margins. These then roll up into a Fair Value that you can compare with the current share price on Simply Wall St’s Community page, update automatically as new news or earnings arrive, and benchmark against other investors. For example, this could include a cautious view that aligns with a Fair Value of about US$27.0 and assumes revenue of US$11.7 million and earnings of US$1.7 million by 2029 on a very high future P/E. Alternatively, it could reflect a more optimistic view that aligns with a Fair Value of about US$51.0 and assumes revenue of US$96.0 million and earnings of US$5.8 million by 2029 on a lower, but still very high, future P/E.

Do you think there's more to the story for Corvus Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.